Rise Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Rise Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17	Closed	-$511	–	1126
2025 Q3	$511	Buy	+17	New	+$510	﹤0.01%	1407

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Rise Advisors's RARE Position: Q4 2025 in Review

Rise Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 17 shares — an estimated $511 sold.

Rise Advisors first reported a position in RARE in Q3 2025 and held it in 1 quarter. The position peaked at $511 in Q3 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Rise Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 17 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $511.
Rise Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 1 quarter.
Rise Advisors's Ultragenyx Pharmaceutical position peaked at $511 in Q3 2025.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.